Use of Amplatzer vascular plugs and Amplatzer duct occluder II additional sizes for occlusion of patent ductus arteriosus: A multi-institutional study

Dennis VanLoozen, Juan Pablo Sandoval, Jeffrey W Delaney, Carlos Pedra, Paulo Calamita, Bharat Dalvi, Damien Kenny, Aoife Cleary, Zahid Amin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Variable patent ductus arteriosus (PDA) morphology and the need to close PDAs in small size patients has led physicians to use Amplatzer Vascular Plugs (AVP) and recently available Amplatzer Duct Occluder II - Additional Sizes (ADO II AS). The purpose of this study was to analyze the safety, efficacy, and complication rates of the ADO II AS and AVPs, specifically AVP II. Methods: All patients undergoing PDA closure with an AVP or ADO II AS from 2011 to 2016 were included. Clinical, echocardiographic, and angiographic data were collected and reviewed. Results: Four hundred and sixty-nine patients were included. Median age was 27 months (0.75–852) and the median weight was 11.4 kg (1–92). There were 51 patients ≤5 kg. Type A PDA was most common in 48% (n = 225), followed by type E (27.5%, n = 129), type D (13%, n = 61), type C (10.2%, n = 48), and type B (1.3%, n = 6). Devices included AVP II (n = 421), ADO II AS (n = 30), and AVP IV (n = 18), left pulmonary artery stenosis occurred in 4.3% (n = 20). One patient required surgery for severe stenosis; the remaining cases were mild and required no intervention. Device embolization occurred in 3 patients (10%) with the ADO II AS. Successful device closure was achieved in 98.9% of cases. Conclusions: The AVP II was highly effective for closing PDAs in smaller babies with varying morphologies and is safe when used in small sized patients with relatively low risk of complications. More studies are warranted to clarify the risks of ADO II AS.

Original languageEnglish (US)
Pages (from-to)1323-1328
Number of pages6
JournalCatheterization and Cardiovascular Interventions
Volume92
Issue number7
DOIs
StatePublished - Dec 1 2018

Fingerprint

Septal Occluder Device
Patent Ductus Arteriosus
Blood Vessels
Equipment and Supplies
Pathologic Constriction
Physicians
Safety
Weights and Measures

Keywords

  • congenital
  • patent ductus arteriosus
  • transcatheter intervention

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Use of Amplatzer vascular plugs and Amplatzer duct occluder II additional sizes for occlusion of patent ductus arteriosus : A multi-institutional study. / VanLoozen, Dennis; Sandoval, Juan Pablo; Delaney, Jeffrey W; Pedra, Carlos; Calamita, Paulo; Dalvi, Bharat; Kenny, Damien; Cleary, Aoife; Amin, Zahid.

In: Catheterization and Cardiovascular Interventions, Vol. 92, No. 7, 01.12.2018, p. 1323-1328.

Research output: Contribution to journalArticle

VanLoozen, Dennis ; Sandoval, Juan Pablo ; Delaney, Jeffrey W ; Pedra, Carlos ; Calamita, Paulo ; Dalvi, Bharat ; Kenny, Damien ; Cleary, Aoife ; Amin, Zahid. / Use of Amplatzer vascular plugs and Amplatzer duct occluder II additional sizes for occlusion of patent ductus arteriosus : A multi-institutional study. In: Catheterization and Cardiovascular Interventions. 2018 ; Vol. 92, No. 7. pp. 1323-1328.
@article{7c386b51d21442eb9e766e0de1f6061d,
title = "Use of Amplatzer vascular plugs and Amplatzer duct occluder II additional sizes for occlusion of patent ductus arteriosus: A multi-institutional study",
abstract = "Background: Variable patent ductus arteriosus (PDA) morphology and the need to close PDAs in small size patients has led physicians to use Amplatzer Vascular Plugs (AVP) and recently available Amplatzer Duct Occluder II - Additional Sizes (ADO II AS). The purpose of this study was to analyze the safety, efficacy, and complication rates of the ADO II AS and AVPs, specifically AVP II. Methods: All patients undergoing PDA closure with an AVP or ADO II AS from 2011 to 2016 were included. Clinical, echocardiographic, and angiographic data were collected and reviewed. Results: Four hundred and sixty-nine patients were included. Median age was 27 months (0.75–852) and the median weight was 11.4 kg (1–92). There were 51 patients ≤5 kg. Type A PDA was most common in 48{\%} (n = 225), followed by type E (27.5{\%}, n = 129), type D (13{\%}, n = 61), type C (10.2{\%}, n = 48), and type B (1.3{\%}, n = 6). Devices included AVP II (n = 421), ADO II AS (n = 30), and AVP IV (n = 18), left pulmonary artery stenosis occurred in 4.3{\%} (n = 20). One patient required surgery for severe stenosis; the remaining cases were mild and required no intervention. Device embolization occurred in 3 patients (10{\%}) with the ADO II AS. Successful device closure was achieved in 98.9{\%} of cases. Conclusions: The AVP II was highly effective for closing PDAs in smaller babies with varying morphologies and is safe when used in small sized patients with relatively low risk of complications. More studies are warranted to clarify the risks of ADO II AS.",
keywords = "congenital, patent ductus arteriosus, transcatheter intervention",
author = "Dennis VanLoozen and Sandoval, {Juan Pablo} and Delaney, {Jeffrey W} and Carlos Pedra and Paulo Calamita and Bharat Dalvi and Damien Kenny and Aoife Cleary and Zahid Amin",
year = "2018",
month = "12",
day = "1",
doi = "10.1002/ccd.27824",
language = "English (US)",
volume = "92",
pages = "1323--1328",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Use of Amplatzer vascular plugs and Amplatzer duct occluder II additional sizes for occlusion of patent ductus arteriosus

T2 - A multi-institutional study

AU - VanLoozen, Dennis

AU - Sandoval, Juan Pablo

AU - Delaney, Jeffrey W

AU - Pedra, Carlos

AU - Calamita, Paulo

AU - Dalvi, Bharat

AU - Kenny, Damien

AU - Cleary, Aoife

AU - Amin, Zahid

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background: Variable patent ductus arteriosus (PDA) morphology and the need to close PDAs in small size patients has led physicians to use Amplatzer Vascular Plugs (AVP) and recently available Amplatzer Duct Occluder II - Additional Sizes (ADO II AS). The purpose of this study was to analyze the safety, efficacy, and complication rates of the ADO II AS and AVPs, specifically AVP II. Methods: All patients undergoing PDA closure with an AVP or ADO II AS from 2011 to 2016 were included. Clinical, echocardiographic, and angiographic data were collected and reviewed. Results: Four hundred and sixty-nine patients were included. Median age was 27 months (0.75–852) and the median weight was 11.4 kg (1–92). There were 51 patients ≤5 kg. Type A PDA was most common in 48% (n = 225), followed by type E (27.5%, n = 129), type D (13%, n = 61), type C (10.2%, n = 48), and type B (1.3%, n = 6). Devices included AVP II (n = 421), ADO II AS (n = 30), and AVP IV (n = 18), left pulmonary artery stenosis occurred in 4.3% (n = 20). One patient required surgery for severe stenosis; the remaining cases were mild and required no intervention. Device embolization occurred in 3 patients (10%) with the ADO II AS. Successful device closure was achieved in 98.9% of cases. Conclusions: The AVP II was highly effective for closing PDAs in smaller babies with varying morphologies and is safe when used in small sized patients with relatively low risk of complications. More studies are warranted to clarify the risks of ADO II AS.

AB - Background: Variable patent ductus arteriosus (PDA) morphology and the need to close PDAs in small size patients has led physicians to use Amplatzer Vascular Plugs (AVP) and recently available Amplatzer Duct Occluder II - Additional Sizes (ADO II AS). The purpose of this study was to analyze the safety, efficacy, and complication rates of the ADO II AS and AVPs, specifically AVP II. Methods: All patients undergoing PDA closure with an AVP or ADO II AS from 2011 to 2016 were included. Clinical, echocardiographic, and angiographic data were collected and reviewed. Results: Four hundred and sixty-nine patients were included. Median age was 27 months (0.75–852) and the median weight was 11.4 kg (1–92). There were 51 patients ≤5 kg. Type A PDA was most common in 48% (n = 225), followed by type E (27.5%, n = 129), type D (13%, n = 61), type C (10.2%, n = 48), and type B (1.3%, n = 6). Devices included AVP II (n = 421), ADO II AS (n = 30), and AVP IV (n = 18), left pulmonary artery stenosis occurred in 4.3% (n = 20). One patient required surgery for severe stenosis; the remaining cases were mild and required no intervention. Device embolization occurred in 3 patients (10%) with the ADO II AS. Successful device closure was achieved in 98.9% of cases. Conclusions: The AVP II was highly effective for closing PDAs in smaller babies with varying morphologies and is safe when used in small sized patients with relatively low risk of complications. More studies are warranted to clarify the risks of ADO II AS.

KW - congenital

KW - patent ductus arteriosus

KW - transcatheter intervention

UR - http://www.scopus.com/inward/record.url?scp=85053298411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053298411&partnerID=8YFLogxK

U2 - 10.1002/ccd.27824

DO - 10.1002/ccd.27824

M3 - Article

C2 - 30196542

AN - SCOPUS:85053298411

VL - 92

SP - 1323

EP - 1328

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 7

ER -